Acro Biomedical Reports Going Concern, No Revenue, and Critical Internal Control Weaknesses in Annual Filing

summarizeSummary

Acro Biomedical's annual report for 2025 paints a dire picture, disclosing a going concern warning, no revenue for two years, significant losses, and material weaknesses in internal financial controls, alongside its status as a shell company with illiquid stock.

check_boxKey Events

• Going Concern Warning Issued

  Management and auditors have expressed substantial doubt about the company's ability to continue as a going concern due to minimal cash, no revenue since December 31, 2022, and recurring losses.

• No Revenue for Two Consecutive Years

  The company reported no revenues for the years ended December 31, 2025, and 2024, incurring net losses of $101,146 and $42,297, respectively, indicating a complete halt in active business operations.

• Material Weaknesses in Internal Controls

  Management concluded that disclosure controls and internal controls over financial reporting were not effective as of December 31, 2025, citing inadequate internal audit functions, insufficient review of financial statements, and a lack of segregation of duties.

• Multiple Auditor Changes Disclosed

  The company dismissed Prager Metis CPAs, LLC on June 30, 2025, engaging KCCW Accountancy Corp., which was subsequently dismissed on January 4, 2026, and replaced by Weinberg & Company, P.A. on the same day. The previous auditor's report also contained a going concern explanatory paragraph.

auto_awesomeAnalysis

This annual report reveals a company in severe distress, with management and auditors explicitly raising substantial doubt about its ability to continue as a going concern. The complete absence of revenue for two consecutive years, coupled with increasing losses and minimal cash, highlights a critical operational failure. The disclosure of material weaknesses in internal controls over financial reporting and ineffective disclosure controls indicates significant governance and risk management deficiencies, increasing the risk of financial misstatement. Furthermore, the company's status as a shell company and its common stock trading on the OTC Expert Market severely limit its ability to raise capital and provide liquidity to investors. The multiple auditor changes, even without stated disagreements, add to the overall red flags surrounding the company's financial health and oversight. Investors face extreme risk given the company's inactive business, funding challenges, and governance issues.